First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study Vivencio Barrios; Carlos Escobar; Vicente Arrarte; Eusebio García; María Rosa Fernández; Luis Miguel Rincón; Cecilia Roldán;

Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study Agustín Blanco Echevarría; Juan De Dios García Díaz; Assumpta Caixas; Núria Plana Gil; Miguel Ángel Rico Corral; Ian Bridges; Nafeesa Dhalwani; Sònia Gatell Menchen; Kausik K. Ray;

Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease Elisenda Climent; David Benaiges; Juan Pedro-Botet;